LEO divests 10 products to Sweden's Karo

5 March 2018 - Deborah Wilkes

Archived

LEO Pharma is divesting a portfolio of 10 prescription and OTC products to Sweden's Karo Pharma for EUR260 million (USD320 million). The Danish company said the move was in line with its 2025 strategy, which focuses on innovative solutions for medical dermatology and "no longer pursues OTC in most markets".

Click tags below for more information on topics:

Karo Pharma

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: